2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W002016
    Phthalazine 253-52-1 99.98%
    Phthalazine is a chemical scaffold. Phthalazine derivatives act as VEGFR-2 inhibitors, PARP-1 inhibitors, and anticancer agents. The complex of phthalazine with silver exhibits broad-spectrum antibacterial and antifungal activities against Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa PAO1, and Candida albicans. Phthalazine derivatives possess potent vasodilatory activity. Phthalazine can be used in research related to colon adenocarcinoma, breast cancer, hypertension, diabetes, and microbial infections.
    Phthalazine
  • HY-W014841
    Sodium hippurate, 98% 532-94-5 99.91%
    Sodium hippurate, 98% is an orally active metabolite. Sodium hippurate, 98% can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Sodium hippurate, 98% decreases NRF2, MMP9 and leads to ROS accumulation. Sodium hippurate, 98% activates TGFβ/SMAD signaling. Sodium hippurate, 98% improves hyperuricemia and colitis. Sodium hippurate, 98% can also be used in cardiovascular disease research. .
    Sodium hippurate, 98%
  • HY-W105735
    1,16-Hexadecanediol 7735-42-4 99.93%
    1,16-Hexadecanediol (Hexadecamethylene glycol) is an ester product.
    1,16-Hexadecanediol
  • HY-W010155R
    Tryptophol (Standard) 526-55-6 99.84%
    Tryptophol (Standard) (Indole-3-ethanol (Standard)) is an analytical standard of Tryptophol (HY-W010155). This product is intended for use in research and analytical applications.Tryptophol is an aromatic alcohol and secondary metabolite produced by microorganisms. Tryptophol induces Apoptosis and cleavage of caspase-8. Tryptophol inhibits Cunninghamella blakesleeana biofilm. Tryptophol has anti-phage infection, biofilm formation regulation, anti-inflammatory, hemolytic, sleep induction, temperature change, seizure susceptibility and immune regulation activities. Tryptophol is used in the research of African trypanosomiasis, sleep disorders, epilepsy.
    Tryptophol (Standard)
  • HY-19908
    BAY-85-8501 1161921-82-9 99.36%
    BAY-85-8501 is a selective, reversible and potent inhibitor of Human Neutrophil Elastase (HNE), with an IC50 of 65 pM.
    BAY-85-8501
  • HY-B1358
    Lincomycin hydrochloride monohydrate 7179-49-9 99.74%
    Lincomycin (U-10149) hydrochloride monohydrate is an orally active lincosamide antibiotic. Lincomycin hydrochloride monohydrate binds to the ribosomes of Gram-positive bacteria to inhibit protein synthesis. Lincomycin hydrochloride monohydrate can inhibit chloroplast translation, disrupt chloroplast integrity, and activate chloroplast-to-nucleus retrograde signaling in Arabidopsis thaliana seedlings. Lincomycin hydrochloride monohydrate induces alterations in lipid profiles and liver injury, disrupts blood glucose and insulin levels, and increases growth rate in mice.
    Lincomycin hydrochloride monohydrate
  • HY-B1900
    Methylprednisolone succinate 2921-57-5 99.67%
    Methylprednisolone succinate (Methylprednisolone hydrogen succinate) is a prodrug of Methylprednisolone (HY-B0260) and glucocorticoid with immunosuppressant and anti-inflammatory activity. Methylprednisolone succinate binds cytosolic glucocorticoid receptors, translocates to nuclei, and modulates target gene transcription. Methylprednisolone succinate alters Bax, Bcl-2, occludin, and ZO-1 expression; attenuates TLR4/NF-κB signaling; suppresses proinflammatory cytokine production and immune cell activation. Methylprednisolone succinate can be used for the research of intracranial haemorrhage, rheumatoid arthritis, multiple sclerosis, preterminal cancer, inflammatory conditions, shock, immediate-type hypersensitivity, acute myocardial ischemia, hypoxic heart muscle damage, and traumatic spinal cord injury.
    Methylprednisolone succinate
  • HY-N2339
    Cholesteryl behenate 61510-09-6 ≥98.0%
    Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.
    Cholesteryl behenate
  • HY-116649
    CB1 antagonist 2 614726-85-1 99.91%
    CB1 antagonist 2 (AM4113) is an orally active cannabinoid receptor type 1 (CB1R) antagonist. CB1 antagonist 2 suppresses appetite, reduces body weight, and blocks addictive behaviors such as heroin addiction, without causing adverse effects like nausea and depression that are associated with traditional CB1 inverse agonists. CB1 antagonist 2 can be used in studies related to obesity and opioid addiction.
    CB1 antagonist 2
  • HY-129035
    PFI-653 2173134-00-2 99.92%
    PFI-653 (Vanin-1-IN-1, compound 3), a chemical probe, is a vanin-1 inhibitor that binds to plasma vanin-1 from mouse, rat, dog, and human. Vanin-1 is a cell surface-associated inositol (GPi) -anchored protein that plays important roles in metabolism and inflammation. PFI-653 inhibits vanin-1 from different species with IC50s of 6.85 nM (human recombinant plasma vanin-1), 9.0 nM (human plasma vanin-1), 24.5 nM (mouse recombinant vanin-1), and 53.4 nM (mouse plasma vanin-1).
    PFI-653
  • HY-161305
    SE-7552 2243575-79-1 99.48%
    SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM. SE-7552 is greater than 850-fold selectivity versus all other known HDAC isozymes. SE-7552 is capable of blocking multiple myeloma growth in vivo. SE-7552 acts as an anti-obesity agent in diet-induced obese mice.
    SE-7552
  • HY-172317
    AZD2389 2791472-12-1 99.65%
    AZD2389 is a potent and orally active FAP inhibitor. AZD2389 can be used for the study of metabolic dysfunction-associated steatohepatitis.
    AZD2389
  • HY-177295
    Naperiglipron 2572566-11-9 99.43%
    Naperiglipron (LY3549492) is an orally active Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC50 of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC50: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research.
    Naperiglipron
  • HY-32351A
    Calcifediol monohydrate 63283-36-3 ≥99.0%
    Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels.
    Calcifediol monohydrate
  • HY-112431A
    Carnostatine hydrochloride 99.89%
    Carnostatine hydrochloride (SAN9812 hydrochloride) is a potent and selective carnosinase 1 (CN1) inhibitor with a Ki of 11 nM for human recombinant CN1. Carnostatine hydrochloride can be used for the treatment of diabetic nephropathy (DN).
    Carnostatine hydrochloride
  • HY-41417S4
    Octanoic acid-13C4 159118-65-7 99.00%
    Octanoic acid-13C4 is the 13C labeled Octanoic acid. Octanoic acid (Caprylic acid) is an oily liquid with a slightly unpleasant rancid taste and used commercially in the production of esters used in perfumery and also in the manufacture of dyes.
    Octanoic acid-13C4
  • HY-14736
    Azilsartan medoxomil 863031-21-4 99.07%
    Azilsartan medoxomil (TAK 491), a prodrug form of Azilsartan (HY-14914), is an orally active angiotensin II receptor type 1 antagonist. Azilsartan medoxomil can be used for the study of essential hypertension.
    Azilsartan medoxomil
  • HY-106539
    Colesevelam hydrochloride 182815-44-7 98.00%
    Colesevelam hydrochloride is an orally active bile acid sequestrant, lipid-lowering agent, and glycemic control agent. Colesevelam hydrochloride binds bile acids in the gastrointestinal tract to form nonabsorbable complexes, interrupts enterohepatic recirculation and increases fecal bile acid elimination. Colesevelam hydrochloride modulates FXR, TGR5, and Cyp7a1 activity and triggers cAMP signaling and GLP-1 release. Colesevelam hydrochloride alters hepatic lipid and glucose metabolism, suppresses hepatic glycogenolysis, reduces hepatic triglyceride and cholesterol levels, and increases LDL-C (low-density lipoprotein cholesterol) clearance. Colesevelam hydrochloride can be used for the research of type 2 diabetes mellitus, hypercholesterolemia, and alcohol-related liver disease.
    Colesevelam hydrochloride
  • HY-139188
    CC260 2411088-26-9 99.45%
    CC260 is a selective PI5P4Kα and PI5P4Kβ inhibitor with Kis of 40 nM and 30 nM, respectively. CC260 does not inhibit or weakly inhibits other protein kinases, such as Plk1 and RSK2. CC260 can be used for cell energy metabolism, diabetes and cancer research.
    CC260
  • HY-145720
    Cemdisiran 1639264-46-2 98.43%
    Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.
    Cemdisiran
Cat. No. Product Name / Synonyms Application Reactivity